Executive SummaryMylan announces May 15 approval to market doxepin-HCl, which recently went off patent. Patent holder Pfizer marketed the drug through its Roerig subsidiary under the brandname Sinequan. Pennwalt licensed the drug from Pfizer and marketed the antidepressant under the tradename Adapin. Mylan said it expects to ship $3 mil. worth of doxepin this quarter, noting that current combined sales of Sinequan and Adapin are $60 mil. per year.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.